Ultragenyx Pharmaceutical Inc - Company Profile
Powered by 
All the sales intelligence you need on Ultragenyx Pharmaceutical Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ultragenyx Pharmaceutical Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ultragenyx Pharmaceutical Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops novel medicines for rare and ultra-rare genetic diseases. The company develops and commercializes biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. It has four marketed products, Mepsevii (vestronidase alfa) for the treatment of Mucopolysaccharidosis (Sly syndrome); Dojolvi (triheptanoin), a purified, synthetic, 7-carbon fatty acid triglyceride for long-chain fatty acid oxidation disorders (LC-FAOD); Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH); and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.
Headquarters
United States of America
Address
60 Leveroni Ct, Novato, California, 94949
Website
www.ultragenyx.com
Telephone
1 302 6587581
No of Employees
1,371
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RARE (NASD)
Revenue (2024)
$673.0M
20.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-1%
(2024 vs 2023)
Market Cap*
$3.3B
Net Profit Margin (2024)
XYZ
15.9%
(2024 vs 2023)
* As of and is in US$
Ultragenyx Pharmaceutical Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Crysvita - X-linked hypophosphatemia and Tumor-Induced Osteomalacia | Crysvita |
| Mepsevii - Mucopolysaccharidosis VII | Mepsevii |
| Dojolvi - Long Chain Fatty-Acid Oxidation Disorders | Dojolvi |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Stake Sale | In November, the company sold an additional 25% stake in future sales of Crysvita (burosumab) in the US and Canada to OMERS for US$400 million. |
| 2025 | Regulatory Approval | In July, the company secured the extended approval from Health Canada for Evkeeza (evinacumab) as an adjunct to diet and other low-density lipoprotein cholesterol-lowering therapies to treat children aged 6-months and older with homozygous familial hypercholesterolemia. |
| 2025 | Regulatory Approval | In June, the company received Breakthrough Therapy Designation for GTX-102 in Angelman syndrome. |
Competitor Comparison
| Key Parameters | Ultragenyx Pharmaceutical Inc | Eli Lilly and Co | Sanofi | Novo Nordisk AS | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | Denmark | United States of America |
| City | Novato | Indianapolis | Paris | Bagsvaerd | Thousand Oaks |
| State/Province | California | Indiana | Ile-de-France | - | California |
| No. of Employees | 1,371 | 50,605 | 76,493 | 64,974 | 31,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel G. Welch | Chairman | Executive Board | 2015 | 67 |
| Emil D. Kakkis, M.D., Ph.D. | Director; Chief Executive Officer; President | Executive Board | 2010 | 64 |
| Howard Horn | Executive Vice President - Corporate Strategy; Chief Financial Officer | Senior Management | 2023 | 47 |
| Eric Crombez | Chief Medical Officer; Executive Vice President | Senior Management | 2023 | 52 |
| Erik Harris | Chief Commercial Officer; Executive Vice President | Senior Management | 2019 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer